Twitter

Archive for August 14th, 2012


Dermatologists’ tips to reduce the signs of aging

Getting better results from your anti-aging products can be as easy as following simple tips from dermatologists.

Read More...

Treatment of Peripheral T-cell Lymphoma

Condition :   Peripheral T-cell Lymphoma Interventions :   Drug: GDPT regimen;   Drug: CHOP regimen Sponsors :   Zhengzhou University;   Mingzhi Zhang;   Zhengzhou University Recruiting – verified August 2012

Read More...

A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors

Condition :   Solid Tumors Intervention :   Drug: thioureidobutyronitrile Sponsors :   Cellceutix Pharmaceuticals;   Cellceutix Pharmaceuticals Not yet recruiting – verified August 2012

Read More...

Pilot Phase II – Erlotinib for Acute Myeloid Leukemia (AML)

Condition :   Leukemia Intervention :   Drug: Erlotinib Sponsors :   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Astellas Pharma Inc Not yet recruiting – verified August 2012

Read More...

AZD2171 in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions :   Leukemia;   Myelodysplastic Syndromes Interventions :   Drug: cediranib maleate;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Procedure: histopathologic examination Sponsors :   National Cancer Institute (NCI);   Mayo Clinic;   National Cancer Institute (NCI) Completed – verified July 2009

Read More...

17-N-Allylamino-17-Demethoxygeldanamycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes

Conditions :   Leukemia;   Myelodysplastic Syndromes Interventions :   Drug: cytarabine;   Drug: tanespimycin Sponsors :   National Cancer Institute (NCI);   Mayo Clinic;   National Cancer Institute (NCI) Completed – verified December 2008

Read More...

Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy

Condition :   Non Small Cell Lung Cancer Interventions :   Radiation: Standard radiochemotherapy to 68 Gy;   Radiation: Dose escalated radiochemotherapy up to 84 Gy Sponsors :   Swedish Lung Cancer Study Group;   Ass. Prof. Jan Nyman Recruiting – verified August 2012

Read More...

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Conditions :   Lymphoma;   Leukemia Interventions :   Drug: CMC-544;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Rituximab;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF Sponsors :   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Pfizer Not yet recruiting – verified August 2012

Read More...

Biomarkers in Plasma Specimens From Patients Treated on Study CALGB-80303

Condition :   Pancreatic Cancer Interventions :   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis Sponsors :   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI) Not yet recruiting – verified August 2012

Read More...

An Observational Study of Tarceva as Second-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Pemetrexed in First-Line (TIME)

Condition :   Non-Small Cell Lung Cancer Intervention :   Sponsors :   Hoffmann-La Roche;   Hoffmann-La Roche Recruiting – verified August 2012

Read More...